Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
$0.40-5.69%
报价 2026-11-06
市值
$111.2M
EV
$94.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -78.3%
$0.40$1.85
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AKBAAkebia Therapeutics, Inc. | $111.2M | -5.7% | -5.1% | 79.5% | – | – | 4.9x | |
| CRVSCorvus Pharmaceuticals, Inc. | $886.6M | +8.3% | -133.3% | 0% | – | – | – | |
| RIGLRigel Pharmaceuticals, Inc. | $740.7M | -13.3% | -3.5% | 91.4% | 2.7x | 9.1x | 11.1x | |
| ZVRAZevra Therapeutics, Inc. | $688.3M | +10.1% | +47.0% | 95% | 9.1x | 6.8x | 18.0x | |
| FDMT4D Molecular Therapeutics, Inc. | $676.7M | +8.9% | -67.5% | 42% | – | – | – | |
| OLMAOlema Pharmaceuticals, Inc. | $641.4M | +8.4% | – | 0% | – | – | – | |
| PRTAProthena Corporation plc | $409.2M | +1.0% | – | -208.6% | – | – | – | |
| CMPXCompass Therapeutics, Inc. | $136.7M | +10.8% | -125.5% | 0% | – | – | – | |
| GOSSGossamer Bio, Inc. | $59.7M | +3.7% | -57.8% | 99.6% | – | – | – | |
| 同行中位数 | – | – | -62.6% | 21% | 5.9x | 8.0x | 14.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。